


In the Claims

Claims 1-22 (Cancelled)

23. (Currently Amended) A method of treating a ~~neovasucular~~ neovascular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of EM-138,



or a hydrolysis product or a metabolite thereof.

24. (Previously Added) The method of Claim 23, wherein the amount administered is between approximately 0.1 and approximately 330/mg/kg/day.

25. (Previously Added) The method of Claim 24, wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

26. (Previously Added) The method of Claim 25, wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

27. (Previously Added) The method of Claim 23, wherein the compound is administered in the form of a tablet or capsule.

28. (Previously Added) The method of Claim 23, wherein the compound is administered in the form of a lozenge, a capsule, a cachet, a tablet, a solution, a suspension, an emulsion, a bolus, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tamport or a pessary.

29. (Previously Added) The method of Claim 23, wherein the administration is oral, parenteral, transdermal or topical.

30. (Previously Added) The method of Claim 23, wherein the administration is bulingual, buccal, rectal, vaginal or nasal.

31. (Previously Added) The method of Claim 23, wherein the eye condition is diabetic retinopathy.

32. (Previously Added) The method of Claim 23, wherein the eye condition is retinopathy of prematurity.

33. (Previously Added) The method of Claim 23, wherein the eye condition is corneal graft rejection.

34. (Previously Added) The method of Claim 23, wherein the eye condition is neovascular glaucoma.

35. (Previously Added) The method of Claim 23, wherein the eye condition is retrolental fibroplasias.

36. (Previously Added) The method of Claim 23, wherein the eye condition is epidemic keratoconjunctivitis.

37. (Previously Added) The method of Claim 23, wherein the eye condition is Vitamin A deficiency.

38. (Previously Added) The method of Claim 23, wherein the eye condition is contact lens overwear.

39. (Previously Added) The method of Claim 23, wherein the eye condition is atopic keratitis.

40. (Previously Added) The method of Claim 23, wherein the eye condition is superior limbic keratitis.

41. (Previously Added) The method of Claim 23, wherein the eye condition is pterygium keratitis sicca.

42. (Previously Added) The method of Claim 23, wherein the eye condition is myopia.

43. (Previously Added) The method of Claim 23, wherein the eye condition is Terrien's marginal degeneration.

44. (Previously Added) The method of Claim 23, wherein the eye condition is marginal keratolysis.

45. (Previously Added) The method of Claim 23, wherein the eye condition is radial keratotomy.

46. (Previously Added) The method of Claim 23, wherein the eye condition is macular degeneration.

47. (Previously Added) The method of Claim 23, wherein the eye condition is post-laser complications.

48. (Previously Added) The method of Claim 23, wherein the eye condition is chronic retinal detachment.

49. (Previously Added) The method of Claim 23, wherein the eye condition is optic pits.

50. (Previously Added) The method of Claim 23, wherein the eye condition is hyperviscosity syndrome.

51. (Previously Added) The method of Claim 23, wherein the eye condition is chronic uveitis.

52. (Previously Added) The method of Claim 23, wherein the eye condition is chronic vitritis.

53. (Previously Added) The method of Claim 23, wherein the eye condition is ocular neovascular disease.

54. (Previously Added) The method of Claim 23, wherein the eye condition is age-related macular degeneration.

55. (Previously Added) The method of Claim 23, wherein the eye condition is presumed ocular histoplasmosis.

56. (Previously Added) The method of Claim 23, wherein the eye condition is an infection causing retinitis or choroiditis.

57. (Previously Added) The method of Claim 23, wherein the eye condition is proliferative vitreoretinopathy.


58. (Previously Added) The method of Claim 23, wherein the eye condition is scleritis.

59. (Previously Added) The method of Claim 23, wherein the eye condition is Eales' disease.

60. (Previously Added) The method of Claim 23, wherein the eye condition is Best's disease.

61. (Previously Added) The method of Claim 23, wherein the eye condition is trachoma.

62. (Currently Amended) The method of treating a ~~neovasucular~~ neovascular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of a composition comprising EM-138,



a hydrolysis product thereof or a metabolite thereof.

63. (Previously Added) The method of Claim 62, wherein the effective amount is between approximately 0.1 and approximately 300 mg/kg/day.

64. (Previously Added) The method of Claim 62, wherein the effective amount is between approximately 0.5 and approximately 50 mg/kg/day.

65. (Previously Added) The method of Claim 62, wherein the effective amount is between approximately 1 and approximately 10 mg/kg/day.

66. (Previously Added) The method of Claim 62, wherein the composition is in the form of a tablet, capsule, a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tampon, or a pessary.

67. (Previously Added) The method of Claim 62, further comprising an additive selected from an anti-oxidant, a buffer, a bacteriostat, a solute which renders the composition isotonic with the blood of the human or the animal, a suspending agent, a thickening agent, a flavoring agent, a gelatin, glycerine, a diluent, or any combination thereof.

68. (Previously Added) The composition of Claim 62, further comprising a biodegradable polymer.